Reverse-phase protein microarrays: application to biomarker discovery and translational medicine

References

• Liotta LA, Espina V, Mehta AI et al. Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell3(4), 317–325 (2003).
   PubMed Web of Science ®Google Scholar
• Petricoin E, Wulfkuhle J, Espina V, Liotta LA. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J. Proteome Res.3(2), 209–217 (2004).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol. Med.10(2), 59–64 (2004).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Bichsel V, Calvert V et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J. Clin. Oncol.23(15), 3614–3621 (2005).
   PubMed Web of Science ®Google Scholar
• Petricoin EF III, Espina V, Araujo RP et al. Phosphoprotein pathway mapping: akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res.67(7), 3431–3440 (2007).
   PubMed Web of Science ®Google Scholar
• Chan SM, Ermann J, Su L, Fathman CG, Utz PJ. Protein microarrays for multiplex analysis of signal transduction pathways. Nat. Med.10(12), 1390–1396 (2004).
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin. Oncol.31(6 Suppl. 16), 10–17; discussion 33 (2004).
   PubMedGoogle Scholar
• Schmelzle K, White FM. Phosphoproteomics approaches to elucidate cellular signaling networks. Curr. Opin. Biotechnol.17(4), 406–414 (2006).
   PubMed Web of Science ®Google Scholar
• Emmert-Buck MR, Bonner RF, Smith PD et al. Laser capture microdissection. Science274(5289), 998–1001 (1996).
   PubMed Web of Science ®Google Scholar
• Bonner RF, Emmert-Buck M, Cole K et al. Laser capture microdissection: molecular analysis of tissue. Science278(5342), 1481–1483 (1997).
   PubMed Web of Science ®Google Scholar
• Chandrasekharappa SC, Guru SC, Manickam P et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science276(5311), 404–407 (1997).
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kohn EC. Stromal therapy: the next step in ovarian cancer treatment. J. Natl Cancer Inst.94(15), 1113–1114 (2002).
   PubMedGoogle Scholar
• Liotta LA, Kohn EC. The microenvironment of the tumour–host interface. Nature411(6835), 375–379 (2001).
   PubMed Web of Science ®Google Scholar
• Haab BB. Antibody arrays in cancer research. Mol. Cell. Proteomics4(4), 377–383 (2005).
   PubMed Web of Science ®Google Scholar
• Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today7(18 Suppl.), S143–S149 (2002).
   PubMedGoogle Scholar
• Steinitz M, Tamir S. An improved method to create nitrocellulose particles suitable for the immobilization of antigen and antibody. J. Immunol. Methods187(1), 171–177 (1995).
   PubMedGoogle Scholar
• Knickerbocker T, Chen JR, Thadhani R, MacBeath G. An integrated approach to prognosis using protein microarrays and nonparametric methods. Mol. Syst. Biol.3, 123 (2007).
   PubMedGoogle Scholar
• Kusnezow W, Syagailo YV, Ruffer S et al. Optimal design of microarray immunoassays to compensate for kinetic limitations: theory and experiment. Mol. Cell. Proteomics5(9), 1681–1696 (2006).
   PubMedGoogle Scholar
• Templin MF, Stoll D, Schrenk M et al. Protein microarray technology. Trends Biotechnol.20(4), 160–166 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu H, Snyder M. Protein chip technology. Curr. Opin. Chem. Biol.7(1), 55–63 (2003).
   PubMed Web of Science ®Google Scholar
• Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics3(1), 56–63 (2003).
   PubMed Web of Science ®Google Scholar
• Knezevic V, Leethanakul C, Bichsel VE et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics1(10), 1271–1278 (2001).
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Charboneau L, Bichsel VE et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene20(16), 1981–1989 (2001).
   PubMed Web of Science ®Google Scholar
• Hultschig C, Kreutzberger J, Seitz H et al. Recent advances of protein microarrays. Curr. Opin. Chem. Biol.10(1), 4–10 (2006).
   PubMed Web of Science ®Google Scholar
• Song S, Li B, Wang L et al. A cancer protein microarray platform using antibody fragments and its clinical applications. Mol. Biosyst.3(2), 151–158 (2007).
   PubMedGoogle Scholar
• Wilson DS, Nock S. Recent developments in protein microarray technology. Angew. Chem. Int. Ed. Engl.42(5), 494–500 (2003).
   PubMed Web of Science ®Google Scholar
• Haab BB. Applications of antibody array platforms. Curr. Opin. Biotechnol.17(4), 415–421 (2006).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov.1(9), 683–695 (2002).
   PubMed Web of Science ®Google Scholar
• Charboneau L. Utility of reverse phase protein arrays: applications to signaling pathways and human body arrays. Brief. Funct. Genomic. Proteomic.1(3), 305–315 (2002).
   PubMedGoogle Scholar
• Belluco C, Mammano E, Petricoin E et al. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin. Chim. Acta357(2), 180–183 (2005).
   PubMedGoogle Scholar
• Gulmann C, Espina V, Petricoin E III et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin. Cancer Res.11(16), 5847–5855 (2005).
   PubMed Web of Science ®Google Scholar
• Rapkiewicz A, Espina V, Zujewski JA et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer111(3), 173–184 (2007).
   PubMed Web of Science ®Google Scholar
• Sheehan KM, Calvert VS, Kay EW et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell. Proteomics4(4), 346–355 (2005).
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Aquino JA, Calvert VS et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics3(11), 2085–2090 (2003).
   PubMed Web of Science ®Google Scholar
• Ekins RP. Multi-analyte immunoassay. J. Pharm. Biomed. Anal.7(2), 155–168 (1989).
   PubMed Web of Science ®Google Scholar
• Kusnezow W, Syagailo YV, Goychuk I, Hoheisel JD, Wild DG. Antibody microarrays: the crucial impact of mass transport on assay kinetics and sensitivity. Expert Rev. Mol. Diagn.6(1), 111–124 (2006).
   PubMed Web of Science ®Google Scholar
• Kusnezow W, Syagailo YV, Ruffer S et al. Kinetics of antigen binding to antibody microspots: strong limitation by mass transport to the surface. Proteomics6(3), 794–803 (2006).
   PubMed Web of Science ®Google Scholar
• Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol. Methods125(1–2), 279–285 (1989).
   PubMed Web of Science ®Google Scholar
• Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J. Immunol. Methods137(1), 103–112 (1991).
   PubMed Web of Science ®Google Scholar
• Hunyady B, Krempels K, Harta G, Mezey E. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J. Histochem. Cytochem.44(12), 1353–1362 (1996).
   PubMed Web of Science ®Google Scholar
• King G, Payne S, Walker F, Murray GI. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J. Pathol.183(2), 237–241 (1997).
   PubMed Web of Science ®Google Scholar
• Tibes R, Qiu Y, Lu Y et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther.5(10), 2512–2521 (2006).
   PubMed Web of Science ®Google Scholar
• Miller LD, Long PM, Wong L et al. Optimal gene expression analysis by microarrays. Cancer Cell2(5), 353–361 (2002).
   PubMed Web of Science ®Google Scholar
• Seong SY. Microimmunoassay using a protein chip: optimizing conditions for protein immobilization. Clin. Diagn. Lab. Immunol.9(4), 927–930 (2002).
   PubMedGoogle Scholar
• Tonkinson JL, Stillman BA. Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate. Front Biosci.7, C1–C12 (2002).
   Google Scholar
• Nijdam AJ, Ming-Cheng Cheng M, Geho DH et al. Physicochemically modified silicon as a substrate for protein microarrays. Biomaterials28(3), 550–558 (2007).
   PubMed Web of Science ®Google Scholar
• Espina V, Geho D, Mehta AI et al. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest.23(1), 36–46 (2005).
   PubMed Web of Science ®Google Scholar
• Grubb RL, Calvert VS, Wulkuhle JD et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics3(11), 2142–2146 (2003).
   PubMed Web of Science ®Google Scholar
• Iyengar P, Espina V, Williams TW et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest.115(5), 1163–1176 (2005).
   PubMed Web of Science ®Google Scholar
• Paweletz CP, Trock B, Pennanen M et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers17(4), 301–307 (2001).
   PubMed Web of Science ®Google Scholar
• Menard C, Susil RC, Choyke P et al. An interventional magnetic resonance imagingtechnique for the molecular characterization of intraprostatic dynamic contrast enhancement. Mol. Imaging4(1), 63–66 (2005).
   PubMedGoogle Scholar
• Becker KF, Schott C, Hipp S et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol.211(3), 370–378 (2007).
   PubMed Web of Science ®Google Scholar
• Fan YH, Hu Z, Li C et al.In vitro expression levels of cell-cycle checkpoint proteins are associated with cellular DNA repair capacity in peripheral blood lymphocytes: a multivariate analysis. J. Proteome Res.6(4), 1560–1567 (2007).
   PubMed Web of Science ®Google Scholar
• Shankavaram UT, Reinhold WC, Nishizuka S et al. Transcript and portein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther.6(3), 820–832 (2007).
   PubMed Web of Science ®Google Scholar
• Machida K, Thompson CM, Dierck K et al. High-throughput phosphotyrosine profiling using SH2 domains. Mol. Cell26(6), 899–915 (2007).
   PubMedGoogle Scholar
• Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature439(7073), 168–174 (2006).
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kondo Y, Kondo S. Roles of mTOR and STAT3 in autophagy induced by telomere 3´ overhang-specific DNA oligonucleotides. Autophagy3(5), 496–498 (2007).
   PubMed Web of Science ®Google Scholar
• Aoki H, Iwado E, Eller MS et al. Telomere 3´ overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA286(18), 2211–2214 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Bhola NE, Lui VW et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol. Cancer Ther.6(4), 1414–1424 (2007).
   PubMed Web of Science ®Google Scholar
• Major SM, Nishizuka S, Morita D et al. AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinformatics7, 192 (2006).
   PubMedGoogle Scholar
• Huang D, Casale GP, Tian J et al. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens. Cancer Epidemiol. Biomarkers Prev.16(7), 1371–1381 (2007).
   PubMed Web of Science ®Google Scholar